Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.

OBJECTIVE To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) for the management of multiple sclerosis (MS) compared to best supportive care in the United States. METHODS Cost-effectiveness analysis was undertaken using a state transition model of disease natural history and the impact of DMTs for the representative Medicare beneficiary with MS. Costs and outcomes were evaluated from the health-care payer perspective using a 50-year time horizon. Natural history data were drawn from a longitudinal cohort study. The effectiveness of the DMTs was evaluated through a systematic review. Utility data were taken from a study of patients with clinically definite MS in Nova Scotia. Resource use and cost data were derived from the Sonya Slifka database and associated literature. RESULTS When based on placebo-controlled evidence, the marginal cost-effectiveness of interferon beta (IFNβ) and glatiramer acetate compared to best supportive care is expected to be in excess of $100,000 per quality-adjusted life-year gained. When evidence from head-to-head trials is incorporated into the model, the cost-effectiveness of 6 MIU IFNβ-1a is expected to be considerably less favorable. Treatment discontinuation upon progression to Expanded Disability Status Scale 7.0 is expected to improve the cost-effectiveness of all DMTs. CONCLUSIONS Further research is required to examine the long-term clinical effectiveness and cost-effectiveness of these therapies. There is no definitive guidance in the United States concerning discontinuation of DMTs; this study suggests that the prudent use of a treatment discontinuation rule may considerably improve the cost-effectiveness of DMTs.

[1]  Ludwig Kappos,et al.  Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.

[2]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[3]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[4]  Peter Lindgren,et al.  Costs and quality of life in multiple sclerosis , 2001, The European Journal of Health Economics (HEPAC).

[5]  J S Wolinsky,et al.  Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability , 1998, Neurology.

[6]  A V Swan,et al.  An assessment of disability rating scales used in multiple sclerosis. , 1991, Archives of neurology.

[7]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[8]  P. Pocklington,et al.  Course of multiple sclerosis , 1982 .

[9]  J. Caro,et al.  Cost of managing an episode of relapse in multiple sclerosis in the United States , 2003, BMC health services research.

[10]  C. Ford.  Long-term experience with current disease-modifying drugs in multiple sclerosis , 2006, Journal of Neurology.

[11]  P Tappenden,et al.  Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. , 2004, Health technology assessment.

[12]  J. Fisk,et al.  A comparison of health utility measures for the evaluation of multiple sclerosis treatments , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[14]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[15]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[16]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[17]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[18]  A. Ghezzi,et al.  Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) , 2002, The Lancet.

[19]  Massimo Filippi,et al.  European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.

[20]  Alastair Compston,et al.  McAlpine's Multiple Sclerosis , 2005 .

[21]  Anthony O'Hagan,et al.  Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. , 2003, BMJ : British Medical Journal.

[22]  J. Wolinsky,et al.  A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients , 2006, Multiple sclerosis.

[23]  D. Frankel,et al.  Disability in elderly people with multiple sclerosis: An analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. , 2004, NeuroRehabilitation.

[24]  D. Goodin,et al.  Randomized, comparative study of interferon β-1a treatment regimens in MS , 2002, Neurology.

[25]  D. Hoaglin,et al.  The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics , 2006, Multiple sclerosis.

[26]  C. Pozzilli,et al.  Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS , 2001, Neurology.